Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
Implantica AG, a medtech company, researches, develops, and sells medical implants for unmet medical needs in Switzerland. Its lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. The company also develops e-InVivo, a sensor implant to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, it develops UriControl, a remote controlled implant to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and MS patients to urinate on demand using the wireless platform. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Implantica AG is a subsidiary of Implantica MediSwiss.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of IMP-A-SDB.ST is 74 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell